Phase 1 Study Findings Support Efficacy of ALTO-101 for the Treatment of Cognitive Impairment in Schizophrenia

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

Related Keywords

United States ,American ,Adam Savitz ,American Society Of Clinical Psychopharmacology ,Clinical Psychopharmacology ,Psychiatric Times ,